[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fqbLlHaGgVO8yMXT-St4bugT26SdUd176gzRP6D6tO8I":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":8,"nonDrugCount":10,"topConditions":11,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"UCSF Benioff Children's Hospital Oakland",[4],55,false,0,8002,38,[12,15,18,21,24,26,28,30],{"name":13,"count":14},"Cardiovascular Disease",9,{"name":16,"count":17},"Dyslipidemia",8,{"name":19,"count":20},"Sickle Cell Disease",6,{"name":22,"count":23},"Thalassemia",5,{"name":25,"count":23},"Inflammation",{"name":27,"count":23},"Insulin Resistance",{"name":29,"count":23},"Anemia, Sickle Cell",{"name":31,"count":32},"Obesity",3,[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,89,115,140,165,200,234,259,277,302,326,351,376,394,419],{"intervention":43,"totalTrials":32,"cells":44},"Simvastatin",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":71,"PHASE4":73,"NA":87},{"trials":46,"activeCount":8},[],{"trials":48,"activeCount":8},[],{"trials":50,"activeCount":8},[51,62],{"nctId":52,"briefTitle":53,"status":54,"phases":55,"primaryCompletion":56,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":61},"NCT01702246","Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease","COMPLETED",[36,37],"2015-05","2015-06","2012-02",24,[19],[43],{"nctId":63,"briefTitle":64,"status":54,"phases":65,"primaryCompletion":66,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":70},"NCT00508027","Simvastatin (Zocor) Therapy in Sickle Cell Disease",[36,37],"2011-12","2007-06",42,[19],[43],{"trials":72,"activeCount":8},[],{"trials":74,"activeCount":8},[75],{"nctId":76,"briefTitle":77,"status":54,"phases":78,"primaryCompletion":79,"start":80,"enrollment":81,"conditions":82,"interventions":86},"NCT00451828","Cholesterol and Pharmacogenetic Study",[39],"2004-10","2002-03",1000,[83,84,85,13],"Hyperlipidemia","Hypercholesterolemia","Coronary Heart Disease",[43],{"trials":88,"activeCount":8},[],{"intervention":90,"totalTrials":91,"cells":92},"Trumenba Vaccine",1,{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":113},{"trials":94,"activeCount":8},[],{"trials":96,"activeCount":8},[],{"trials":98,"activeCount":8},[],{"trials":100,"activeCount":8},[],{"trials":102,"activeCount":8},[103],{"nctId":104,"briefTitle":105,"status":54,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT02569632","Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)",[39],"2016-12","2015-01",18,[111],"Meningococcal Infections",[90],{"trials":114,"activeCount":8},[],{"intervention":116,"totalTrials":91,"cells":117},"ezetimibe",{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":138},{"trials":119,"activeCount":8},[],{"trials":121,"activeCount":8},[],{"trials":123,"activeCount":8},[],{"trials":125,"activeCount":8},[],{"trials":127,"activeCount":8},[128],{"nctId":129,"briefTitle":130,"status":54,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT00794677","Effects of Ezetimibe on the Absorption of Oxidized Cholesterol",[39],"2008-02","2008-09","2006-06",26,[84],[116],{"trials":139,"activeCount":8},[],{"intervention":141,"totalTrials":91,"cells":142},"Inhaled Aztreonam",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":163},{"trials":144,"activeCount":8},[],{"trials":146,"activeCount":8},[],{"trials":148,"activeCount":8},[],{"trials":150,"activeCount":8},[],{"trials":152,"activeCount":8},[153],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":23,"conditions":160,"interventions":162},"NCT03158116","The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas","TERMINATED",[39],"2020-02-20","2017-07-01",[161],"Tracheostomy Infection",[141],{"trials":164,"activeCount":8},[],{"intervention":166,"totalTrials":167,"cells":168},"tazarotene",2,{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":194,"PHASE4":196,"NA":198},{"trials":170,"activeCount":8},[],{"trials":172,"activeCount":8},[],{"trials":174,"activeCount":8},[175,185],{"nctId":176,"briefTitle":177,"status":54,"phases":178,"primaryCompletion":179,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},"NCT00489086","Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face",[37],"2012-06","2004-07",36,[183],"Neoplastic Syndrome",[166],{"nctId":186,"briefTitle":187,"status":54,"phases":188,"primaryCompletion":179,"completion":189,"start":180,"enrollment":190,"conditions":191,"interventions":193},"NCT00783965","Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back",[37],"2014-01",34,[192],"Skin Carcinoma",[166],{"trials":195,"activeCount":8},[],{"trials":197,"activeCount":8},[],{"trials":199,"activeCount":8},[],{"intervention":201,"totalTrials":167,"cells":202},"Arginine",{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":204,"activeCount":8},[],{"trials":206,"activeCount":8},[],{"trials":208,"activeCount":8},[209,218],{"nctId":210,"briefTitle":211,"status":54,"phases":212,"primaryCompletion":67,"completion":67,"start":213,"enrollment":214,"conditions":215,"interventions":217},"NCT01796678","Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial",[37],"2000-09",56,[216],"Vaso-occlusive Pain Episodes",[201],{"nctId":219,"briefTitle":220,"status":54,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":227},"NCT00513617","Effectiveness of Arginine as a Treatment for Sickle Cell Anemia",[37],"2007-09","2008-01","2004-06",128,[29],[201],{"trials":229,"activeCount":8},[],{"trials":231,"activeCount":8},[],{"trials":233,"activeCount":8},[],{"intervention":235,"totalTrials":91,"cells":236},"alpha-lipoic acid and acetyl-L-carnitine",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":238,"activeCount":8},[],{"trials":240,"activeCount":8},[],{"trials":242,"activeCount":8},[243],{"nctId":244,"briefTitle":245,"status":54,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":251},"NCT01054768","Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease",[37],"2013-04","2009-08",37,[29],[235,252],"Control",{"trials":254,"activeCount":8},[],{"trials":256,"activeCount":8},[],{"trials":258,"activeCount":8},[],{"intervention":252,"totalTrials":91,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":262,"activeCount":8},[],{"trials":264,"activeCount":8},[],{"trials":266,"activeCount":8},[267],{"nctId":244,"briefTitle":245,"status":54,"phases":268,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":269,"interventions":270},[37],[29],[235,252],{"trials":272,"activeCount":8},[],{"trials":274,"activeCount":8},[],{"trials":276,"activeCount":8},[],{"intervention":278,"totalTrials":91,"cells":279},"L-Glutamine",{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":296,"PHASE4":298,"NA":300},{"trials":281,"activeCount":8},[],{"trials":283,"activeCount":8},[],{"trials":285,"activeCount":8},[286],{"nctId":287,"briefTitle":288,"status":54,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT01048905","Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension",[37],"2014-03","2009-03",13,[294,19,22],"Pulmonary Hypertension",[278],{"trials":297,"activeCount":8},[],{"trials":299,"activeCount":8},[],{"trials":301,"activeCount":8},[],{"intervention":303,"totalTrials":91,"cells":304},"GDC-0449",{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":320,"PHASE4":322,"NA":324},{"trials":306,"activeCount":8},[],{"trials":308,"activeCount":8},[],{"trials":310,"activeCount":8},[311],{"nctId":312,"briefTitle":313,"status":54,"phases":314,"primaryCompletion":189,"completion":189,"start":248,"enrollment":315,"conditions":316,"interventions":319},"NCT00957229","To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)",[37],41,[317,318],"Basal Cell Nevus Syndrome","Gorlin Syndrome",[303],{"trials":321,"activeCount":8},[],{"trials":323,"activeCount":8},[],{"trials":325,"activeCount":8},[],{"intervention":327,"totalTrials":91,"cells":328},"Arginine hydrochloride",{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":345,"PHASE4":347,"NA":349},{"trials":330,"activeCount":8},[],{"trials":332,"activeCount":8},[],{"trials":334,"activeCount":8},[335],{"nctId":336,"briefTitle":337,"status":54,"phases":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT00029731","Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients",[37],"2005-07","2001-08",30,[29,343],"Pneumonia",[327],{"trials":346,"activeCount":8},[],{"trials":348,"activeCount":8},[],{"trials":350,"activeCount":8},[],{"intervention":352,"totalTrials":91,"cells":353},"Vismodegib",{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":355,"activeCount":8},[],{"trials":357,"activeCount":8},[],{"trials":359,"activeCount":8},[360],{"nctId":361,"briefTitle":362,"status":54,"phases":363,"primaryCompletion":364,"completion":364,"start":365,"enrollment":59,"conditions":366,"interventions":368},"NCT01556009","Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas",[37],"2015-12","2012-04",[317,367],"Gorlin's Syndrome",[352,369],"Aminolevulinic acid %20 topical solution",{"trials":371,"activeCount":8},[],{"trials":373,"activeCount":8},[],{"trials":375,"activeCount":8},[],{"intervention":369,"totalTrials":91,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":379,"activeCount":8},[],{"trials":381,"activeCount":8},[],{"trials":383,"activeCount":8},[384],{"nctId":361,"briefTitle":362,"status":54,"phases":385,"primaryCompletion":364,"completion":364,"start":365,"enrollment":59,"conditions":386,"interventions":387},[37],[317,367],[352,369],{"trials":389,"activeCount":8},[],{"trials":391,"activeCount":8},[],{"trials":393,"activeCount":8},[],{"intervention":395,"totalTrials":91,"cells":396},"Ketamine",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":413,"PHASE4":415,"NA":417},{"trials":398,"activeCount":8},[],{"trials":400,"activeCount":8},[],{"trials":402,"activeCount":8},[403],{"nctId":404,"briefTitle":405,"status":54,"phases":406,"primaryCompletion":407,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},"NCT03296345","Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis",[37],"2018-04","2016-06",62,[19,411],"Vaso-Occlusive Crisis",[395],{"trials":414,"activeCount":8},[],{"trials":416,"activeCount":8},[],{"trials":418,"activeCount":8},[],{"intervention":420,"totalTrials":91,"cells":421},"Zinc sulfate",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":423,"activeCount":8},[],{"trials":425,"activeCount":8},[],{"trials":427,"activeCount":8},[428],{"nctId":429,"briefTitle":430,"status":54,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":59,"conditions":435,"interventions":437},"NCT01062009","Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children",[36,37],"2014-10","2014-11","2008-11",[436],"Critical Illness",[420],{"trials":439,"activeCount":8},[],{"trials":441,"activeCount":8},[],{"trials":443,"activeCount":8},[]]